Evidence mapPaperPMID 39859366Full record

ReviewInternational journal of molecular sciences2025

Utility of Protein Markers in COVID-19 Patients.

López-Biedma Alicia, Onieva-García María Ángeles, Martín-García Desirée, Redondo Maximino, García-Aranda Marilina

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

López-Biedma AliciaResearch and Innovation Unit, Hospital Costa del Sol, Autovía A-7 km 187, 29603 Marbella, Spain.ORCID 0000-0001-9518-3409
Onieva-García María ÁngelesPreventive Medicine and Public Health Unit, Hospital Universitario Reina Sofia, 14004 Cordoba, Spain.
Martín-García DesiréeResearch and Innovation Unit, Hospital Costa del Sol, Autovía A-7 km 187, 29603 Marbella, Spain.
Redondo MaximinoResearch and Innovation Unit, Hospital Costa del Sol, Autovía A-7 km 187, 29603 Marbella, Spain.ORCID 0000-0001-5559-4246
García-Aranda MarilinaResearch and Innovation Unit, Hospital Costa del Sol, Autovía A-7 km 187, 29603 Marbella, Spain.ORCID 0000-0003-3759-4044

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 has been a challenge at the healthcare level not only in the early stages of the pandemic, but also in the subsequent appearance of long-term COVID-19. Several investigations have attempted to identify proteomic biomarkers in an attempt to improve clinical care, guide treatment and predict possible patient outcomes. Proteins such as C-reactive protein (CRP) or interleukin 6 (IL-6) are clear markers of severe disease, but many others have been proposed that could help in risk stratification and in the prediction of specific complications. This review aims to bring together the most relevant studies in this regard, providing information to identify the most notable biomarkers in relation to COVID-19 found to date.

Indexed as

BiomarkersCOVID-19C-Reactive ProteinHumansInterleukin-6ProteomicsSARS-CoV-2BiomarkersC-Reactive ProteinInterleukin-6biomarkersCOVID-19proteomicrisktreatment

Identifiers

PMID39859366
PMCPMC11766239

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.